Cited by 44Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The relevance of beta-amyloid on markers of Alzheimer’s disease in clinically normal individuals and factors that influence these associations

Open access
Mormino, Elizabeth C.·2014·Neuropsychology Review

Abstract

Aberrant accumulation of beta-amyloid (Aβ) is thought to be an early event in a biological cascade that eventually leads to Alzheimer's disease (AD). Along these lines, many clinically normal (CN) older individuals have evidence of beta-amyloid (Aβ) accumulation, which may be indicative of preclinical AD. However, relationships between Aβ and "downstream" AD markers are often inconsistent across studies. These inconsistencies may be due to the presence of other age-related processes that also influence AD markers, as well as additional risk factors that interact with Aβ to influence downstream changes. For instance, it is possible that the effect of Aβ is modified by neurodegeneration, genetics, sex-differences and cognitive reserve. Thus, a multivariate approach to determining risk of AD within CN participants may be more appropriate than reliance on Aβ status alone. An understanding of how additional risk factors interact with Aβ to influence an individual's trajectory towards AD is essential for characterizing preclinical AD and has implications for prevention trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11065-014-9267-4

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The correlation between hallmark lesions and the presence and severity of disease is modest.

    “the correlation between hallmark lesions and the presence and severity of disease is modest”

    From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [104]

    The Cognition section (page not provided) describes a subtle association between beta-amyloid and cross-sectional cognitive performance in clinically normal individuals. That supports a modest association in this specific setting, but not the broader claim about hallmark lesions collectively correlating with the presence and severity of disease. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • It is well established that the pathological burden of diverse lesions and proteinopathies can be substantial in people who are living independently and are clinically asymptomatic.

    “it is well established that the pathological burden of diverse lesions and proteinopathies can be substantial in people who are living independently and are clinically asymptomatic [103–107].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 146 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Mormino, E. C.
Affiliations
Harvard University (US)
Corresponding author
Mormino, Elizabeth C.
Venue
Neuropsychology Review
Published
2014-08-10
Volume
24
Issue
3
Pages
300-312
ISSN
  • 1040-7308 (ISSN-L)
  • 1573-6660
OpenAlex
W2023331656
Cited by
44
References
146
Citations by year
2026: 2 · 2025: 4 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 2 · 2020: 1 · 2019: 4 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 8 · 2013: 1
FWCI
0.78
Type
journal article
Language
en
Open access
Locations
  • Neuropsychology Review (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Mayo Clinic
  • National Institutes of Health
  • National Institute on Aging (F32AG044054, P01AG036694)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
amyloid-beta, Alzheimer's disease, preclinical Alzheimer's disease, neurodegeneration, genetic risk factors, sex differences, cognitive reserve, risk factors, prevention trials
MeSH terms
Age Factors, Alzheimer Disease, Atrophy, Brain, Cognition, Female, Humans, Male, Memory Disorders, Risk Factors, Sex Factors, Biomarkers, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review